Christie Hospital, Manchester
Gefitinib shows promise in treating non-small cell lung cancer
Published in Hospital Business Week, May 16th, 2004
According to a study from England, "Traditional cytotoxic anticancer therapies do not differentiate between tumor and host cells, and research efforts have been focused on finding new agents that target tumor tissue. Gefitinib ('Iressa', ZD1839) is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks signal pathways implicated in solid tumor growth and metastasis."
"In phase II trials, gefitinib 250 mg/day demonstrated efficacy in the control of advanced non-small-cell lung cancer (NSCLC) in patients who had undergone prior...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hospital Business Week
More Articles from Hospital Business Week
- Berlex, Inc.
Hormone maker comments on WHI estrogen-only study data - Eli Lilly & Co.
Estrogen therapy more effective for increasing bone density than raloxifene - Geriatrics
Older Americans forgo retirement to keep their 9-to-5 schedules - Healthcare Coverage
Bill offered to reform Medicare prescription law - Healthcare Coverage
McKesson receives approval to offer Medicare drug discount card - Medicaid
Michigan faces higher payments for state and federal program - More from this issue of Hospital Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
